RxDoctor Payments Data

Cynthia Delavalle

Adult Health · Poughkeepsie, NYNPI 1730666900

Payments from drug & device makers

$1,332in general payments, 2019–2025

Across 57 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$432
  • Collegium Pharmaceutical, Inc.$156
  • AbbVie$121
  • Neurelis, Inc.$120
  • Scilex Pharmaceuticals Inc.$112
  • Boston Scientific$84
  • plus $307 from 7 others

What the payments were for

  • Food & beverage$1,332100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,332 in reported general payments places this provider in the 70th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$54,530
Medicare patients
119
Services billed
678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide35$80,071
MovantikNaloxegol Oxalate35$16,676
Xtampza ErOxycodone Myristate23$10,009
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen245$8,941
Buprenorphine27$8,654
Oxycodone Hcl334$6,792
ZtlidoLidocaine17$5,783
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen169$2,465
Morphine Sulfate ErMorphine Sulfate13$1,379
Lidocaine20$1,357
Pregabalin43$995
Fentanyl13$841
Gabapentin54$763
Amitriptyline Hcl12$666
Hydromorphone Hcl29$578

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$432$80,07135 claims
Collegium Pharmaceutical, Inc.Xtampza Er$156$10,00923 claims
Scilex Pharmaceuticals Inc.Ztlido$112$5,78317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,828 adult health providers in New York.

Other adult health in Poughkeepsie

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →